Liquid Biopsy in Breast Cancer: A Modern Approach to Cancer Detection and Monitoring

Liquid Biopsy in Breast Cancer: A Modern Approach to Cancer Detection and Monitoring

Liquid biopsy is an emerging approach in cancer diagnostics that analyzes tumor-derived material circulating in the blood. Unlike a conventional tissue biopsy, which requires removing a sample of tumor tissue, liquid biopsy uses a blood sample to investigate molecular signals released by cancer cells into the bloodstream.

In breast cancer, liquid biopsy is being studied and increasingly applied for specific clinical purposes, particularly for detecting circulating tumor DNA (ctDNA), identifying molecular alterations, monitoring treatment response, and detecting signs of residual disease or recurrence. However, its clinical role depends on the specific test, cancer stage, and clinical context.

What Is a Liquid Biopsy?

A liquid biopsy is a minimally invasive blood-based test designed to identify biological material associated with a tumor. One of its most important targets is circulating tumor DNA (ctDNA)—small fragments of DNA released by tumor cells into the bloodstream.

Depending on the technology used, liquid biopsy may analyze:

• Circulating tumor DNA (ctDNA)

• Cell-free DNA (cfDNA)

• Circulating tumor cells (CTCs)

• Tumor-derived RNA and other molecular biomarkers

Because these biomarkers can carry genetic and molecular information from cancer cells, their analysis may provide insights into the characteristics and behavior of a tumor.

How Is Liquid Biopsy Used in Breast Cancer?

Liquid biopsy does not currently replace mammography, breast MRI, ultrasound, or tissue biopsy for the initial diagnosis of breast cancer. Instead, its potential value is particularly important in molecular characterization and disease monitoring.

1. Molecular Profiling

Analysis of circulating tumor DNA can help identify specific genetic alterations present in a tumor. Depending on the test, this information may support treatment selection, particularly in advanced or metastatic breast cancer.

2. Monitoring Treatment Response

Changes in ctDNA levels or specific molecular alterations may provide information about how a tumor is responding to treatment. In research and selected clinical settings, changes in circulating biomarkers are being investigated as an earlier indication of treatment response or resistance.

3. Detecting Molecular Changes Associated With Resistance

Cancer cells can acquire genetic alterations that allow them to become resistant to treatment. Serial liquid biopsy testing may help identify emerging molecular changes and provide additional information for clinical decision-making.

4. Monitoring Minimal or Molecular Residual Disease

After treatment, very small amounts of tumor-derived DNA may remain in the body even when conventional imaging does not show measurable disease. Highly sensitive ctDNA assays are being investigated for detecting molecular residual disease (MRD) and estimating the risk of recurrence.

5. Monitoring Advanced or Metastatic Breast Cancer

In metastatic breast cancer, liquid biopsy can provide a relatively convenient way to repeatedly assess tumor-associated molecular alterations without requiring repeated invasive tissue sampling. This can be particularly useful when obtaining a tissue biopsy is difficult or when the tumor may have changed over time.

Liquid Biopsy vs. Tissue Biopsy

Liquid and tissue biopsies provide different types of information and should not be considered interchangeable.

A tissue biopsy obtains a physical sample of the tumor and remains an essential component of breast cancer diagnosis. It allows pathologists to evaluate tumor morphology and determine important characteristics such as histological type, receptor status, and other pathological features.

A liquid biopsy, in contrast, analyzes tumor-associated material found in the blood. It is minimally invasive and can be repeated more easily, making it particularly attractive for longitudinal monitoring.

In some clinical situations, liquid biopsy may complement tissue-based testing rather than replace it.

How Does a Liquid Biopsy Work?

The process generally involves several steps:

Blood collection → Plasma separation → Isolation of cell-free DNA → Detection of tumor-derived DNA → Molecular analysis → Clinical interpretation

Because ctDNA can represent only a small fraction of the total cell-free DNA in the bloodstream, highly sensitive analytical methods are required. Depending on the purpose of testing, techniques may include targeted sequencing, digital PCR, or next-generation sequencing (NGS).

The sensitivity and clinical usefulness of a liquid biopsy depend on factors such as tumor burden, cancer stage, biological characteristics of the tumor, assay design, and the amount of ctDNA circulating in the blood.

Can Liquid Biopsy Detect Breast Cancer Early?

This is one of the most actively researched applications of liquid biopsy.

Researchers are investigating whether circulating tumor DNA, circulating tumor cells, methylation patterns, and other blood-based biomarkers can identify cancer at an earlier stage—potentially before it becomes detectable through conventional diagnostic approaches.

However, liquid biopsy should not currently be considered a universal replacement for established breast cancer screening methods such as mammography. A negative liquid biopsy result does not necessarily rule out breast cancer, particularly when the amount of tumor-derived material in the blood is very low.

Therefore, liquid biopsy results should always be interpreted within the broader clinical and diagnostic context.

The Role of Liquid Biopsy in Precision Medicine

One of the major advantages of liquid biopsy is its potential contribution to precision oncology.

Breast cancer is not a single disease. Tumors can differ substantially in their molecular characteristics, and these characteristics may change during disease progression or treatment.

By providing access to tumor-derived molecular information through a blood sample, liquid biopsy may support a more dynamic understanding of cancer biology. Combined with genomic testing, clinical information, imaging, and pathological findings, these data can contribute to more individualized approaches to cancer management.

Our Role in the Breast Cancer Diagnostic Journey

Our company focuses on helping individuals navigate the increasingly complex landscape of genetic and precision health information.

We do not view a liquid biopsy as an isolated test. Instead, we consider it one component of a broader, evidence-based pathway that may include risk assessment, appropriate screening, genetic or molecular testing, interpretation, and referral to qualified healthcare professionals.

Our role may include:

• Providing educational information about liquid biopsy and molecular cancer testing

• Helping individuals understand which types of genetic or molecular tests may be relevant to their circumstances

• Supporting access to appropriate testing pathways through qualified laboratories and healthcare professionals

• Helping organize and contextualize genetic or molecular test information

• Facilitating referral to physicians or specialists when further clinical evaluation is appropriate

• Supporting informed discussions between patients and their healthcare providers

Importantly, our services are designed to support—not replace—the clinical judgment of physicians, oncologists, genetic counselors, radiologists, and other qualified healthcare professionals.

The Future of Liquid Biopsy in Breast Cancer

Liquid biopsy is rapidly evolving as research continues to improve the sensitivity and specificity of blood-based cancer biomarkers.

Future applications may include more sensitive detection of molecular residual disease, improved monitoring of treatment response, identification of emerging resistance mechanisms, and potentially earlier cancer detection.

As these technologies develop, the interpretation of liquid biopsy results will require careful integration with clinical history, imaging, pathology, and other molecular data.

For individuals considering genetic or molecular testing, understanding which test is appropriate, why it is being performed, and how the results may influence clinical care is just as important as the technology itself.

Important Note

Liquid biopsy is an evolving area of cancer diagnostics. Its clinical applications vary according to the specific assay and clinical situation. It should not be used as a substitute for recommended breast cancer screening, diagnostic imaging, or tissue biopsy when these are clinically indicated. Test results should be interpreted by qualified healthcare professionals in the context of the individual's medical history and other diagnostic findings.